Patently Innovative

Table of contents

1. Cover image
2. Title page
3. Table of Contents
4. Copyright
5. Dedication
6. Acknowledgements
7. List of figures and tables
8. List of abbreviations
9. About the author
10. Chapter 1: Introduction
    1. Abstract:
    2. 1.1 The emergence of global pharmaceutical linkage
    3. 1.2 Canadian pharmaceutical linkage regulations
    4. 1.3 Organization
11. Chapter 2: Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy
    1. Abstract:
    2. 2.1 Drug approval
    3. 2.2 Patents
    4. 2.3 Linkage regulations
    5. 2.4 IPR rights and innovation policy
12. Chapter 3: Empirical analysis of drug approval
    1. Abstract:
    2. 3.1 Introduction
    3. 3.2 Analysis
    4. 3.3 Results
    5. 3.4 Discussion
    6. 3.5 Interpretation of data
    7. 3.6 Study limitations
    8. 3.7 Assessing the lifecycle approach: the long view
    9. 3.8 Government as representative public agent
    10. 3.9 Summary and conclusions
13. Chapter 4: Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage
    1. Abstract:
    2. 4.1 Introduction
    3. 4.2 Methods
    4. 4.3 Results
    5. 4.4 Discussion
14. Chapter 5: Empirical analysis of drug patenting in multiple high-value cohorts
    1. Abstract:
    2. 5.1 Introduction
    3. 5.2 Methods
    4. 5.3 Results
    5. 5.4 Discussion
    6. 5.5 Summary and conclusions
15. Chapter 6: Implications of empirical data: are pharmaceutical linkage regulations a success?
    1. Abstract:
    2. 6.1 Introduction
    3. 6.2 Debate preceding Bill C-91
    4. 6.3 ‘Original policy intent’
    5. 6.4 ‘Patent-specific’ analysis
    6. 6.5 Statutory interpretation
    7. 6.6 Revisiting the empirical data
    8. 6.7 Summary and conclusions
16. Chapter 7: Future directions: testable hypotheses and evolution toward global pharmaceutical linkage
    1. Abstract:
    2. 7.1 Hypotheses regarding cluster-based drug development
    3. 7.2 Globalization of pharmaceutical linkage
17. Index